Steven O’Day will be presenting an update on botensilimab programs at Nature Conferences’s event – Agenus
Quoting Agenus on X:
“Tomorrow, Dr. Steven O’Day will be speaking at Nature Conferences’ Cancer Immunotherapy event, presenting an update on our botensilimab programs.”
Read further
Source: Agenus/X
Steven O’Day serves as Agenus’ Chief Medical Officer. He is responsible for leading the expansion of the company’s presence in the I-O field. A pioneer in CTLA-4 inhibition, Dr O’Day played key roles in the advancement of cancer therapies Yervoy and Opdivo and has been the principal investigator in more than 200 clinical trials. Before joining Agenus, he was Executive Director of the John Wayne Cancer Institute and Cancer Clinics at Providence St. John’s Health Center and Director of the Melanoma and Cutaneous Oncology Research Center. Steven was a visiting scholar in philosophy and medical ethics at Oxford, received his MD from Johns Hopkins, and was a Fellow at the Dana Farber/Harvard Cancer Center.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023